Last reviewed · How we verify
NCT06920641
Effects of Tagatose on Glycemic Response and Gastrointestinal Microbiota in Healthy Adults
NA trial testing Tagatose in Glucose Intolerance in 55 participants. Currently enrolling.
31 December 2025
Quick facts
| Lead sponsor | PepsiCo Global R&D |
|---|---|
| Phase | NA |
| Status | Recruiting now |
| Study type | INTERVENTIONAL |
| Allocation | randomized |
| Design | crossover |
| Masking | quadruple |
| Primary purpose | basic science |
| Enrollment | 55 |
| Start date | 25 March 2025 |
| Primary completion | 31 December 2025 |
| Estimated completion | 31 December 2025 |
| Sites | 1 location across Canada |
Drugs / interventions tested
- Tagatose — full drug profile →
- Placebo
Conditions studied
- Glucose Intolerance — all drugs for Glucose Intolerance →
- Microbial Colonization — all drugs for Microbial Colonization →
Sponsor
PepsiCo Global R&D — full company profile →
Who can join
Adults 18 to 50, any sex, with Glucose Intolerance or Microbial Colonization. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
The primary objective of this clinical-trial is to determine, in subjects with impaired fasting glucose (IFG) and/or insulin resistance (IR), if tagatose meets the definition of a prebiotic, namely that consuming tagatose for 4 weeks selectively stimulates the selective growth of bacteria in the colon and is associated with a health benefit (oral glucose tolerance) when compared to consuming the control treatment (10g sucrose) for 4 weeks.
Publications & conference data
No peer-reviewed publications indexed yet for this trial.
Verify or expand the search:
- PubMed search for NCT06920641
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other recruiting trials for Glucose Intolerance
Currently open trials in the same condition.
- NCT06684106 — Ursodeoxycholic Acid Attenuates Statin-Induced Impaired Glucose Tolerance · NA · recruiting
- NCT05775627 — Sleep and Metabolism · NA · recruiting
- NCT06366399 — The Acute T-Rex (Timing of Resistance Exercise) Study · NA · recruiting
- NCT05874635 — Signos DM2 Empowerment Study (SIGNOS-CGM-EMPOWER-201-2022) · NA · active not recruiting
- NCT05468255 — The Impact of Removal of Exercise on Glycemic Control and Vascular Health in Older Active Adults · NA · recruiting
Other PepsiCo Global R&D trials
Trials by the same sponsor.
- NCT07429201 — Comparing an Electrolyte-Carbohydrate Beverage to Water During Ramadan · NA · completed
- NCT07400614 — Evaluating the Impact of Energy Drink Formulas on Alertness for an Extended Period · NA · recruiting
- NCT07427654 — Determination of the Glycemic Index of Products Varying in Levels of Refined and Whole Grain Corn · NA · completed
- NCT07298863 — The Effect of Hydration Status on Substrate Oxidation at Rest and During Light and Moderate Exercise · NA · recruiting
- NCT07217834 — Effects of a Glycerol-Electrolyte Beverage on Fluid Balance in Healthy Euhydrated Men and Women · NA · recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT06920641 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by PepsiCo Global R&D
- Last refreshed: 10 April 2025
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT06920641.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing